fulvestrant

Fulvestrant (ZM 182780) is an estrogen receptor (ER) antagonist (IC50=9.4 nM) and an agonist of GPR30. Fulvestrant has antitumor activity, inhibiting cell proliferation and inducing apoptosis and autophagy.

Fulvestrant 3-β-D-Glucuronide, a glucuronide and sulfate conjugate metabolite of the pure anti-estrogenic steroid Fulvestrant, is utilized in breast cancer research [1].

Fulvestrant S enantiomer is the less active S enantiomer of Fulvestrant. Fulvestrant is a potent estrogen receptor antagonist with an IC50 of 9.4 nM.

Fulvestrant sulfone is a synthetic estrogen receptor antagonist.

Fulvestrant R enantiomer is the less active R enantiomer of Fulvestrant. Fulvestrant is a potent estrogen receptor antagonist with an IC50 of 9.4 nM.

Fulvestrant-d3 is a deuterated compound of Fulvestrant. Fulvestrant has a CAS number of 129453-61-8. Fulvestrant is a potent Estrogen Receptor antagonist (IC50: 9.4 nM).

Endoxifen, also known as N-desmethyl-4-hydroxytamoxifen, is a chemical that is under development for estrogen receptor-positive breast cancer. It is also being evaluated as an antipsychotic for treatment of mania and other psychotic disorders. Endoxifen is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group. It is an active metabolite of tamoxifen and has been found to be effective in patients that have failed previous hormonal therapies (tamoxifen, aromatase inhibitors, and fulvestrant). The prodrug tamoxifen is metabolized by the CYP2D6 enzyme to produce afimoxifene (4-hydroxytamoxifen) and endoxifen.